- Conditions
- Metastatic Breast Cancer
- Interventions
- Everolimus, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 11
- States / cities
- *see Various Departments*, California • Fountain Valley, California • Loma Linda, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1249–1272
of 1,489
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis B
- Interventions
- Vaccination to prevent hepatitis B virus infection
- Biological
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • Chicago, Illinois • Cleveland, Ohio
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Tamibarotene, Venetoclax, Azacitidine
- Drug
- Lead sponsor
- Syros Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 10 more
- Conditions
- Solid Tumor, Adult
- Interventions
- Enhanced education, Usual care education
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Chico, California • Sacramento, California
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- PAL-CHW-PDAC, Usual Care with Attention Control
- Behavioral · Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Months and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Necrotizing Fasciitis
- Interventions
- Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT), Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)
- Device · Other
- Lead sponsor
- Kerecis Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Drug Resistant Epilepsy
- Interventions
- Survey questionnaires, Epilepsy Visit Planner, Questionnaires for Providers
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
- Interventions
- Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
- Other · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 30 Years to 74 Years · Female only
- Enrollment
- 100,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2029
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Irvine, California • Los Angeles, California + 8 more
- Conditions
- Health Behavior
- Interventions
- Usual care, Clinic-based visits, Standard pediatric surveillance, Structured, schedule-based visits, Enhanced pediatric surveillance, Technology enhanced care coordination, :Individually-tailored visits, Clinic-based visits and community visits
- Behavioral
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Dorchester, Massachusetts
- Conditions
- Malignant Lung Neoplasm
- Interventions
- Standard Follow-Up Care, Caregiver-Related Intervention or Procedure, Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Narcolepsy, Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
- Interventions
- Brief MBI, Standard MBI, Extended MBI
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Glioblastoma, Glioblastoma, IDH-wildtype, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Interventions
- NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • St Louis, Missouri
- Conditions
- Cancer
- Interventions
- Survivorship Care Plan (SCP), Coordinated PCP visit
- Behavioral
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Asthma
- Interventions
- Intervention Subjects
- Behavioral
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Venous Thormboembolism
- Interventions
- Enoxaparin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Cleveland, Ohio
- Conditions
- Oropharyngeal Squamous Cell Carcinoma, HPV-mediated Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabete Type 2, Diabetes, Overweight , Obesity
- Interventions
- Intensive Multicomponent Healthy Eating and Weight Loss Intervention, Enhanced Usual Diabetes Care
- Behavioral
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Dermatomyositis
- Interventions
- Immunoglobulin (Hizentra)
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chemotherapy-related Cognitive Impairment
- Interventions
- Low-Intensity Walking Intervention, Control Group Intervention
- Behavioral
- Lead sponsor
- Ellis Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Schenectady, New York
- Conditions
- Obstructive Sleep Apnea
- Interventions
- HFNC, Low flow oxygen by nasal cannula
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 1 Day to 12 Months
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Cincinnati, Ohio
- Conditions
- Pain, Postoperative, Ankle Fractures
- Interventions
- Ropivacaine, Epinephrine, Morphine, 0.9% sodium chloride solution
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Solid Tumor
- Interventions
- Rilvegostomig, Volrustomig, Sabestomig, Pembrolizumab, AZD9592, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
- Biological · Combination Product
- Lead sponsor
- Presage Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 9
- States / cities
- Shreveport, Louisiana • The Bronx, New York • Chapel Hill, North Carolina + 5 more
- Conditions
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
- Interventions
- AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 674 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
- Conditions
- Cortical Excitability, Healthy, TMS, Menstrual Cycle, Menopause
- Interventions
- Transcranial Electrical Stimulation, Transcranial Magnetic Stimulation, TES + TMS
- Device
- Lead sponsor
- Carnegie Mellon University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania